Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Press Releases
Palatin Technologies, Inc.  
November 14, 2024

Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment

avatar profile Olean Times Herald

Olean Times Herald


Local & Social